The role of PPAR activation during the systemic response to brain injury by unknown
JOURNAL OF 
NEUROINFLAMMATION
Losey et al. Journal of Neuroinflammation  (2015) 12:99 
DOI 10.1186/s12974-015-0295-7RESEARCH Open AccessThe role of PPAR activation during the systemic
response to brain injury
Patrick Losey1,2, Emma Ladds3, Maud Laprais2, Borna Geuvel1, Laura Burns1, Regis Bordet2*
and Daniel C Anthony1,2*Abstract
Background: Fenofibrate, a PPAR-α activator, has shown promising results as a neuroprotective therapy, with
proposed anti-inflammatory and anti-oxidant effects. However, it displays poor blood-brain barrier permeability
leading to some ambiguity over its mechanism of action. Experimentally induced brain injury has been shown to
elicit a hepatic acute phase response that modulates leukocyte recruitment to the injured brain. Here, we sought to
discover whether one effect of fenofibrate might include the suppression of the acute phase response (APR)
following brain injury.
Methods: A 1-h intraluminal thread middle cerebral artery occlusion (MCAO) model followed by a 6-h reperfusion
was performed in C57/BL6 mice. Quantitative reverse transcriptase-polymerase chain reaction was then used to
measure hepatic expression of chemokine (C-X-C motif) ligand 1 (CXCL1), chemokine ligand 10 (CXCL10) and
serum amyloid A-1 (SAA-1), and immunohistochemical analysis was used to quantify brain and hepatic neutrophil
infiltration following stroke.
Results: The MCAO and sham surgery induced the expression of all three acute phase reactants. A 14-day
fenofibrate pre-treatment decreased reactant production, infarct volume, and neutrophil recruitment to the brain
and liver, which is a hallmark of the APR.
Conclusions: The data highlight a novel mechanism of action for fenofibrate and lend further evidence towards
the promotion of its use as a prophylactic therapy in patients at risk of cerebral ischaemia. Further research is
required to elucidate the mechanistic explanation underlying its actions.
Keywords: Fenofibrate, PPAR-α activator, Acute phase response, Middle cerebral artery occlusionBackground
Worldwide, approximately 15 million individuals suffer a
stroke each year [1], with over 150,000 taking place in
the United Kingdom (UK) [2]. Whilst 20% are fatal,
making stroke the fourth leading cause of death in the
UK [2], more than 50% of sufferers survive but remain
dependent on others for daily activities [3]. Stroke is
therefore a significant public health concern, estimated
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individuals and healthcare systems worldwide.
Pathologically, more than 85% of strokes are primarily
ischaemic, with the remaining minority being haemor-
rhagic in origin. Both produce an ischaemic core sur-
rounded by a threatened penumbra [4] which, whilst
hypoxic and functionally impaired, initially manages to
preserve its metabolic status [5]. Common neuroprotec-
tive strategies have targeted this area shortly after the
primary cerebrovascular event in an attempt to minimise
tissue loss. However, whilst moderately effective in
otherwise healthy rodents, in humans, this strategy has
proved less successful and alternative approaches have
been sought [6]. One possibility involves highlighting
high-risk individuals and prophylactically deployinghis is an Open Access article distributed under the terms of the Creative
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iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Losey et al. Journal of Neuroinflammation  (2015) 12:99 Page 2 of 10long-acting neuroprotective agents in an attempt to re-
duce stroke incidence or outcomes [7].
Peroxisome-proliferator-activated receptors [PPARs]
have been proposed as possible neuroprotectants. These
ligand-activated transcription factors [8] exist in three
currently identified isoforms: PPARα, PPARγ and PPARβ/δ
[9, 10] with fibrates, such as the widely used and well-toler-
ated lipid-lowering agent fenofibrate, having greatest affin-
ity for the former [11]. Upon activation, PPARα forms a
heterodimer with the retinoid x receptor, binds to peroxi-
some proliferator response elements on enhancer regions
and initiates or represses gene transcription [12].
Whilst the lipid-lowering effects of PPARα agonists
are well known, the demonstration of independent neu-
roprotection in permanent [13] and transient [14] is-
chaemic stroke models has been proposed to result from
local anti-inflammatory actions, including a reduction of
oxidative stress [15]. Supporting evidence for such a role
includes the discovery of the pro-inflammatory leukotri-
ene B4 as a PPARα activating ligand [16]; regulatory ef-
fects on the pro-inflammatory mediators IL-6 and IL-12
[17] via induction of IκBα [15] and increased expression
of copper/zinc superoxide dismutase (SOD), glutathione
peroxidase (GPX), glutathione reductase (GR) and gluta-
thione S-transferase (GST) - all potent mediators of oxi-
dative stress [18]. Moreover, pre-treatment with specific
PPARα agonists has been shown to lower the post-
ischaemic levels of reactive oxygen species (ROS) and in-
flammatory markers - at least partially through negative
transcriptional effects on the NF-kB pathway [19].
These anti-inflammatory effects were initially pro-
posed to occur centrally due to the known distribution
of PPARα [20]; however, synthetic agonists have a poor
brain bioavailability [18]. Thus, the neuroprotective ac-
tions mediated by fibrates may be primarily, or at least
partially, occurring within the periphery and this has
been supported by the discovery of a more widespread
PPARα distribution [21]. Indeed, brain injury alone has
been shown to elicit a hepatic acute phase response
(APR) [22, 23]. Initiated by macrophages or monocytes,
this peripheral response to central homeostatic distur-
bances promotes the production of cytokines and other
hepatic acute phase proteins [18] and thus enhances
centrally directed leukocytosis [22] as well as initiating
other homeostatic pro-inflammatory alterations [24].
Pharmacologically targeting the APR in experimentally
derived brain injury models has been shown to reduce
hepatic and central neutrophil migration [25]. Central
inflammation is generally accepted to be detrimental to
neurons [26], exacerbating neurodegeneration, and long-
term neutrophil recruitment has been linked to axonal
damage [27], blood-brain barrier [BBB] breakdown and
axonal demyelination [28]. Therefore, reducing this in-
flammatory response to the initial injury caused by theprimary cerebrovascular event may result in neuropro-
tective effects within the ischaemic penumbra.
The significance of the role of the liver in the APR fol-
lowing brain injury has been demonstrated by the deple-
tion of hepatic Kupffer cells, which markedly reduces
central neutrophil recruitment [29]. Moreover, inhibition
of increased hepatic NFkB expression following brain in-
jury resulted in considerable reduction of neutrophil mi-
gration to the central nervous system [30]. There is
good evidence that such a peripheral systemic inflamma-
tory response is induced following stroke. Ischaemic
stroke patients undergo an increase in peripheral CRP
and IL-6 [31], with higher levels of the latter related to
larger lesion volumes and poorer outcomes [32]. Experi-
mentally induced peripheral inflammatory responses are
linked with poorer stroke outcomes [33], with a reduc-
tion in the volume of ischaemic damage associated with
an antibody-mediated depletion of peripheral neutro-
phils [25].
Subsequent studies have attempted to identify mech-
anistic links between the peripheral hepatic APR and the
central inflammatory response. Ischaemic stroke models
and peripheral IL-1 administration have been shown to
increase levels of CXCL10/interferon-inducible protein-
10 in unstimulated splenocytes [26], activating its recep-
tor CXCR3. CXCL10 has been shown to be important in
central leukocyte recruitment in stroke models [34], par-
ticularly in ischaemic cortex [35], with elevated levels
also seen in a variety of other diseases [35]. Alongside its
role as a chemoattractant for monocytes and activated T
lymphocytes, CXCL10 has been implicated in glial cell
migration [36] - making its splenic upregulation in stroke
models a point of particular interest [26] and raising the
possibility of a role for CXCL10 in the coordination of
leukocyte migration in response to stroke.
This dual-purpose study aims to characterise the hepatic
APR following brain injury in experimental stroke models
and examine whether the neuroprotective actions of feno-
fibrate could be exerted through an attenuation of this
peripheral response.
Materials and methods
Animals and fenofibrate administration
All animal protocols were performed in strict accordance
with the Ethical Committee in Animal Experimentation of
Nord-Pas-de-Calais (C2EA-75) and the European com-
munity legislation (2010/63/UE). The experiments are re-
ported in accordance with the ARRIVE guidelines. Male
Wistar rats (mean weight 300 g) (Elevage Janvier, Le
Genest Saint-Isle, France) were used. Animals were ran-
domly assigned to three different groups (naive, sham and
MCAO). Experimental data were monitored by blinded
investigator for group allocation. Forty-two rats were fed a
control diet (standard chow for Harlan), and 42 were fed a
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200 mg/kg) for 14 days prior to the induction of ischae-
mia. This dose was selected following previous studies
that have been found to be neuroprotective and able to
normalise the ischaemic proteome [37].
Focal cerebral ischaemia model
Transient focal cerebral ischaemia was induced by a 60-
min middle cerebral artery occlusion (MCAO) proced-
ure as previously described [38]. Briefly, anaesthesia was
induced by intraperitoneal chloral hydrate administra-
tion (300 mg/kg). The caudal artery was exposed, cannu-
lated with a 24G polyethylene catheter and connected to
a blood pressure monitor. The mean arterial blood pres-
sure was monitored throughout, and blood samples were
taken before, during and after ischaemia to measure
blood pH, PaO2 and PaCO2. The right carotid arteries
were exposed through a midline cervical incision, and
the common and external carotid arteries were ligated
with a silk suture. An aneurysm clip was placed across
the internal carotid artery, and an arteriotomy was made
in the common carotid artery stump, allowing the intro-
duction of a monofilament nylon suture. The suture was
gently advanced into the internal carotid artery and
passed into the intracranial circulatory system as far as
the start of the middle cerebral artery. After 60 min, the
suture was carefully removed to allow reperfusion. Sham
control animals were subjected to the same procedure
up to and including insertion of the filament, but this
was then quickly removed. Forty-two (n = 7 per group)
animals were killed 6 h after the procedure, fresh frozen
tissue was collected and 42 (n = 7 per group) were killed
and perfusion fixed at 24 h for estimation of infarct size
and histology. For infarct volume measurements, sec-
tions were stained by cresyl violet. The unstained area of
the brain was defined as the infarct zone. Infarcted cor-
tical and subcortical areas and hemispheric areas were
calculated separately for each coronal slice using the image
analysis software Color Image 1.32 (NIMH, Bethesda, MD,
USA) after digitization. It should be noted that no infarct
was detectable in the sham animals. The sham experi-
ments served as a control for the non-CNS trauma associ-
ated with the insertion of the filament, which would be
expected to induce an acute phase response in the liver.
Tissue processing/collection
Six hours after the procedure, rats were anaesthetised
with IP sodium pentobarbitone (CEVA Sante Animale)
and transcardially perfused with heparinised 0.9% sa-
line. Hepatic tissue samples for PCR analysis were rap-
idly dissected to minimise mRNA degradation and
stored at −80°C. Further, animals were killed at 24 h
and were perfusion fixed with 4% paraformaldehyde
(PFA); samples of the liver and the brain were removedand placed in 100% neutral buffered formalin for 7 days
at 4°C before being processed to wax.
Immunohistochemical analysis
The wax blocks containing the liver samples were cut in
10-μm-thick sections. Three sections were taken per rat
and mounted onto SuperFrost Plus slides (Thermo Sci-
entific, Waltham, MA, USA). Antigen retrieval was per-
formed using a Sequenza staining system. For the
hepatic samples, the rabbit anti-mouse antibody MBS-2
(a neutrophil-specific in-house antibody) was used as the
primary antibody and omitted from control slides. A bi-
otinylated goat anti-rabbit IgG antibody was added as a
secondary antibody to label bound MBS-2. Finally, the
bound MBS-2-anti-IgG complexes were revealed by ap-
plication of an avidin (A) biotinylated (B) horseradish
peroxidase macromolecular complex (C) and its sub-
strate diaminobenzidine (DAB) (VectorElite ABC kit,
Vector Laboratories Inc., Burlingame, CA, USA). The
colour change at the sites of localised reaction facilitated
identification of the complexes and counterstaining with
Mayer’s haematoxylin solution-aided neutrophil identifi-
cation (Supplementary methods).
When processing the brain tissue, wax blocks were cut
until the MCAO was reached. Three sections were cut
sequentially and then three omitted prior to the next
sections, in order to get a representation of the whole
area affected. The neutrophil-staining process was simi-
lar to the liver except that an anti-polymorphonuclear
antibody (anti-PMN) was the primary antibody and
0.05% cresyl violet was the counterstain. For both tissue
types, sections were subsequently dehydrated with in-
creasing concentrations of ethanol, washed in xylene
and preserved using a DePeX mounting medium (VWR
International Ltd, Poole, England).
Each slide was blinded, randomly assigned a number
and subsequently subjected to analysis using light mi-
croscopy. This involved counting the cells present within
the five areas of highest neutrophil density using a
Nikon eclipse E200 microscope fitted with an eyepiece
graticule of known area, thus revealing the average neu-
trophils per square millimeter.
RNA analysis
Total RNA extraction from snap-frozen liver samples
was undertaken using the Qiagen RNeasy® Mini Kit
(Qiagen Ltd, Crawley, UK) and cDNA then synthesised
using a Taqman Reverse Transcription reagent kit
(Applied Biosystems, Warrington, UK) - both according
to manufacturers’ instructions (Supplementary methods).
The primer and probe sequences (Table 1) for the acute
phase protein serum amyloid A-1 (SAA-1), and the mouse
chemokines CXCL1 and CXCL10 were added to 10 ng
RNA and a Roche Light Cycler 480 (Roche Diagnostics,
Table 1 Primers and probes for the mouse chemokines CXCL1, CXCL10 (IP-10) and for the acute phase protein SAA-1
Marker and probe Forward primer Reverse primer
CXCL1 (probe #83) AGCCACACTCCAACACAGC CAGCGCTGCACAGAGAAG
SAA-1 (probe #32) CCAGGATGAAGCTACTCACCA TAGGCTCGCCACATGTCC
CXCL10 (probe #3) GCTGCCGTCATTTTCTGC TCTCACTGGCCCGTCATC
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tive reverse transcriptase-polymerase chain reaction
(RT-PCR). The housekeeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used to nor-
malise the input RNA for each reaction. Results were
expressed as copies of chemokines or SAA/ng of input
RNA corrected to GAPDH.Statistical analysis
Statistical analysis was performed using the Prism 6.0
(GraphPad, La Jolla, CA, USA) statistical analysis soft-
ware. Normality was determined using a Kolmogorov-
Smirnov (K-S) test and Levene’s test was carried out to
test for equality of variance. Two-way ANOVA was used
throughout followed by post hoc t-tests corrected for
multiple comparisons using the Holm-Sidak method.
Results
Fenofibrate pre-treatment reduces the total infarct
volume
Whilst it has been shown previously that fenofibrate pre-
treatment in MCAO animals significantly reduces the
total infarct volume [39], it was important to show that
this was also the case in the present set of experiments.
Here, infarct volume was reduced by the fenofibrate diet
from 50 to 28 mm3, which was mostly attributable to a

















Figure 1 Pre-treatment with fenofibrate significantly reduces total infarct volume
representative cresyl-violet-stained coronal sections through the territory of the MC
absence of infarct in a (iii) sham surgery animal. (b) Total, cortical and subcortical in
significance denoted by asterisks where P<0.05. Bars are mean± SD.Brain neutrophil recruitment following focal cerebral
ischaemia is attenuated by 14-day fenofibrate
pre-treatment
In the same animals, immunohistochemistry was used to
assess the effects of experimental stroke on hepatic and
brain neutrophil recruitment. Both sham and MCAO
procedures increased the levels of neutrophils present in
the liver after 24 h, and fenofibrate diet had a significant
impact on the number of neutrophils recruited to the
liver after surgery (Figure 2a-d). The number of neutro-
phils present in the liver has been shown to be a good
surrogate for assessing the APR induction, and the diet
produced a 78% reduction (P = 0.034) in the number of
neutrophils present in the liver following MCAO at 24 h
(Figure 3a). Indeed, in the fenofibrate-treated animals,
the number of neutrophils present was reduced to near
control levels. The reduction in infarct volume brought
about by the fenofibrate treatment was also associated
with a significant reduction in the number of neutrophils
present within the brain parenchyma (Figure 3b). No
neutrophils could be detected in the brains of naive or
sham animals.
Hepatic CXCL10, CXCL1 and SAA-1 expression levels
increase following focal cerebral ischaemia or sham
surgery and are reduced by fenofibrate pre-treatment
A significant increase was observed in hepatic mRNA
expression for CXCL10, CXCL1 and SAA-1 following*
t Cortical infarct Subcortical infarct
Control diet
in MCAO mice compared to standard diet regimes. (a) Photomicrographs of
A reveal infarcts in the (i) control diet and (ii) fenofibrate treated animals and





Figure 2 Representative photomicrographs of hepatic MBS1-stained neutrophils (brown stain) 24 h after (a, c) transient MCAO or (b, d) sham surgery.
The liver of animals fed with the fenofibrate diet, (c, d), contained fewer neutrophils compared to standard diet animals and were not, in appearance,
different from naive controls. The livers are counterstained with haematoxylin (blue). Photomicrographs of neutrophils in infarcted cortical
tissue of animals at 24 h in animals fed (e) standard diet or (f) the fenofibrate diet.
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pared to naïve rat (Figure 4). Two-way ANOVA revealed
that diet and group had a significant impact on the out-
come for all transcripts (P < 0.05). When the effect of
diet on the outcome in each surgical group was com-
pared in post hoc tests, the fenofibrate diet significantly
reduced the expression of each of the acute phase reac-
tants in the sham group (Figure 4). In the MCAO group,
only CXCL10 (P = 0.0055) and SAA-1 (P = 0.0014) ex-
pression levels were significantly reduced by the fenofi-
brate diet.
Discussion
Experimental stroke induces peripheral inflammatory
markers associated with the hepatic APR
Acute brain injuries have been shown to induce a per-
ipheral APR, including an increase in hepatic inflamma-
tory markers [23]. If modified, post-injury outcomes are
improved [39], highlighting this response as a favourable
therapeutic target. In this study, we have demonstrated
increased levels of the hepatic inflammatory markersCXCL1, CXCL10 and SAA following ischaemic injury
caused by MCAO occlusion and sham procedures. We
have also shown that this is accompanied by an increase
in the number of neutrophils present within the liver.
Both the markers of the APR and the neutrophil recruit-
ment to the brain and to the liver are inhibited by the
administration of the PPARα agonist.
MCAO occlusion and the sham procedures resulted in
the induction of a peripheral APR. We suspect that part
of the response in the latter group was due to systemic
injury resulting from the surgical procedure per se [40].
Whilst sham procedures including insertion of monofila-
ments into the external carotid artery have also been
shown to generate ischaemic lesions independently from
those generated by MCAO, there was no evidence of
any infarct following closer histological inspection. It is
therefore most likely that the tissue injury associated
with the induction of the MCAO lesions contributes to-
wards the systemic APR [41]. Most would now accept
that peripheral immune status is likely to affect the out-































Figure 3 Neutrophil recruitment after 24 h. The number of
neutrophils present after 24 h in the (a) liver or (b) brain of naive,
sham-operated or transient MCAO rats which have been either fed a
standard or fenofibrate-enhanced diet. Note that pre-treatment with
fenofibrate significantly reduced the number of hepatic neutrophils
present at 24 h following MCAO and the number of neutrophil in
the brain. Bars represent mean ± SD. Statistical significance denoted























































































Figuret 4 Effect of fenofibrate pretreatment on the acute phase
response at 6 h following surgery. (a) The expression of hepatic
CXCL10 (mRNA copies/ng of total RNA input corrected to GAPDH),
(b) the expression of hepatic CXCL1 and (c) hepatic expression of
SAA-1. Note that sham surgery alone induces the induction of all
transcripts, which are sensitive to fenofibrate pre-treatment. Bars are
mean ± SD. *P < 0.05, ***P < 0.0001.
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peripheral activation of the immune system, which needs
to be considered when evaluating the impact of new
therapy. As such, therapy that effectively reduces the
APR induced by the sham surgery is likely to have a
more beneficial effect on the outcome of the ischaemic
brain injury than would be the case if the induction of
the MCAO was atraumatic. This might account for
some of the differences that are observed between the
transient lesion induced by endothelin-1 and the fila-
ment and is likely to bias results.
The early acute phase protein CXCL1 is structurally
and functionally homologous to human interleukin-8
(IL-8), with a role in mediating neutrophil chemotaxis
and lysosomal enzyme release [42]. Increased hepatic
levels have been demonstrated following direct intras-
triatal challenge with IL-1β, suggesting its involvement
in a generic hepatic response to brain injury [33], and ele-
vated IL-8 levels have been identified as early predictive
markers of mortality in humans following severe traumaticbrain injury [36]. CXCL1/IL-8 is therefore an attractive
target both in terms of attenuating the APR and improving
functional outcomes. Indeed, CINC-1 neutralisation has
been shown to reduce hepatic neutrophil recruitment [33],
whilst inhibition of the CXCL1/IL-8 receptor CXCR2 in a
transient MCAO model resulted in reduced infarct size
and improved neurological functional recovery [35], sug-
gesting that theoretical benefits translate in practice.
Increased brain levels of CXCL10 and its receptor
CXCR3 have previously been demonstrated in response
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splenocytes following ischaemic brain injury [44]. In
this study, and for the first time, we also demonstrate
an increase in hepatic expression of this chemokine.
CXCL-10 has been shown to be chemotactic for
monocytes and activated T lymphocytes [45], but it is
also known to be chemoattractant for neutrophils [46]
and thus the inhibition of CXCL10 might be particu-
larly useful as it would inhibit early recruitment of
neutrophils and the ongoing recruitment of monocytes
that continues for a longer period after a stroke.
SAA-1, along with SAP, has been identified as the
major murine acute phase protein in the APR [19].
Intrastriatal challenge with recombinant IL-1β has
been associated with significantly increased hepatic
SAA-1 expression [22]. In this study, hepatic levels
were increased tenfold over the magnitude seen previ-
ously, raising the possibility of a greater specific role
for SAA-1 following ischaemic brain injury, or, more
likely, that the MCAO model produces a greater hep-
atic APR than direct central inflammatory challenge.
SAA-1 enhances the migration of monocytes and poly-
morphonuclear cells to sites of inflammation [47],
with potentially detrimental effects. For example,
chronically raised levels have been shown to correlate
with the severity of atherosclerotic lesions [48] and
the protein has also been associated with the produc-
tion of reactive oxygen species [49]. It is interesting to
speculate about whether the levels seen in our experi-
ment would have remained chronically elevated fol-
lowing ischaemic injury and the detrimental impact
this may have inflicted on the ischaemic penumbra
and potential functional outcome.
In this study, we have shown increased levels of hep-
atic and brain neutrophils in both sham and MCAO
animals associated with generation of a hepatic APR
in response to ischaemic brain injury and upregulation
of peripheral chemokines. This neutrophil infiltration
is in accordance with the results of previous studies,
which have also demonstrated significant hepatic
damage following neutrophil recruitment [33]. Mech-
anistically, neutrophil-mediated oxidative stress and
subsequent cellular dysfunction or necrosis may con-
tribute to the hepatic derangement seen in patients
who have suffered acute CNS injury [50]. Early acute
hepatic failure has been shown to upregulate central
cyto/chemokines, including CXCL1, which mediate
neurotoxic effects independently of microglial activa-
tion [51]. It is therefore easy to postulate the
development of a feedforward cycle of ongoing periph-
eral inflammation and organ dysfunction following
ischaemic brain injury that results in ongoing central
inflammation, impeding the response to stroke and
worsening functional outcomes.Mechanistic underpinnings for peripheral APR generation
The mechanistic signalling pathways that underlie hep-
atic APR generation following ischaemic brain injury are
currently unknown. The rapid temporal profile of acute
phase protein increase at a significant distance from the
site of direct injury has led to speculation that neural
mechanisms may be responsible. Neuro-immune interplay
has previously been reported: sympathetic stimulation has
been shown to induce local release of norepinephrine in
lymphoid tissues, resulting in T cell differentiation and se-
cretion of cytokines such as TNF, IFN-y [44] and IL-6
[52], whilst direct acetylcholine inhibits release of hepatic
pro-inflammatory cytokines [42].
An alternative or complementary hypothesis centres
around humoral messengers within the CNS released
following generalised brain injury into the vascular bed
via the perivascular spaces [33]. However, no such
messenger has currently been identified. Presumed can-
didates would include pro-inflammatory cytokines, how-
ever both IL-6 and IL-1b knockout mice can produce a
normal APR and there is no increase in plasma cytokine
levels following brain injury, which would be expected if
such a signalling pathway were responsible [33]. This
study also does not provide any supportive evidence for
this theory, and further research is therefore needed to
identify humeral messengers if they do indeed contribute
to APR generation.
Fenofibrate pre-treatment reduces hepatic and brain
neutrophil recruitment following ischaemic brain injury
and is associated with a limited APR
In this study, dietary pre-treatment with fenofibrate
reduced brain and hepatic neutrophil recruitment following
ischaemic brain injury. The damaging contribution of neu-
trophils to ischaemic brain damage is well documented
[53], with reduction of the PMN infiltration associated with
reduced infarct volume [54], increased cerebrovascular per-
fusion [55] and improved neurological outcomes in MCAO
models [53]. Therefore, it seems likely that prevention of
PMN infiltration is one mechanism by which fenofibrate
may exert its neuroprotective effects. However, it is ex-
pected that a reduction in infarct volume would be associ-
ated with a reduction in brain neutrophil numbers. Thus, it
is difficult to argue that the fenofibrate diet has a direct ac-
tion on neutrophil recruitment to the brain and that it is
this that leads to a reduction in infarct volume. However,
the early suppression of hepatic chemokine expression and
leukocyte recruitment to the liver can be directly attributed
to the fenofibrate treatment that is well known to exert
anti-inflammatory actions by antagonising nuclear factor
(NF)-κB [56]. To further support the argument that feno-
fibrate exerts its principal beneficial action after ischaemia
in the periphery is that, under normal physiological condi-
tions, the blood-brain barrier is highly impermeable to
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fenofibrate-loaded microparticles have been shown to re-
duce infarct volumes following ischaemic stroke [57], the
fenofibrate employed in this study, as in others, was given
systemically and would be excluded from the brain. Thus,
it can be speculated that both the hepatic and central re-
ductions in neutrophil recruitment are mediated by per-
ipheral signalling via the attenuating effects on cytokine
expression. The temporal expression profile of the chemo-
attractant CXCL1 following MCAO generation demon-
strates a rapid transient increase, with a peak at 4 h,
followed by a decline to baseline [33]. Mechanistically, this
rapid rise may result in neutrophil mobilisation from the
bone marrow, whilst the decline allows for generation of a
central-peripheral chemokine gradient resulting in central
neutrophil migration, which is supported by multiple
studies demonstrating a delay in peak brain neutrophil
levels relative to plasma expression of CXCL1 [34].
One of the major challenges to neuroprotective agents
is the cascade of detrimental interconnected but inde-
pendent dysregulated immune pathways that contribute
to and are exacerbated by ischaemic brain injury. Inflam-
mation is a major contributor to all the major central and
peripheral comorbidities associated with stroke including
atherosclerosis, hyperlipidaemia, diabetes, obesity, hyper-
tension and infection [58], thus the most effective neuro-
protective agents must be able to exert inhibiting effects
over multiple elements of the immune response under-
lying these processes. In this study, fenofibrate is shown to
reduce CXCL1 expression and neutrophil levels, CXCL10
and thus mononuclear infiltration and SAA-1 and there-
fore general systemic inflammation. Such a variety of dir-
ect anti-inflammatory effects, along with those already
demonstrated on oxidative stress [15] and production of
reactive oxygen species [19], supports the potential
efficacy of fenofibrate, a widely used, well-tolerated lipid-
lowering agent, as a neuroprotective agent.
Conclusions
In this study, we quantified the hepatic APR following
ischaemic brain injury and demonstrated an associated
increase in hepatic and central neutrophil recruitment.
Pre-treatment with peripheral fenofibrate reduced levels
of hepatic CXCL1, IP-10 and SAA-1, which was associ-
ated with reduction in infarct volume and brain and
hepatic neutrophil influx, which provides a mechanistic
insight into how fenofibrate can be an effective neuro-
protective agent following ischaemic stroke.
Supplementary methods
Immunohistochemical analysis
Antigen retrieval was undertaken by microwaving
(650 W) the slides in 0.01-M citrate acid buffer (pH 6)
before washing them in a solution of PBS and 0.05%Tween 20 (PBS-T). Endogenous peroxidase activity was
quenched by incubation in a solution of 0.3% H2O2 in
methanol for 20 min. Following three further washes
with PBS-T, the tissues were placed in a Sequenza stain-
ing system (Shandon, UK) for 1 h, with non-specific
binding sites blocked using 10% normal goat serum
(Vector Laboratories Inc., Peterborough, UK). Avidin
was added in a 1:50 ratio to eliminate endogenous hep-
atic biotin, with excess avidin subsequently removed in a
PBS-T wash.
All solutions of antibodies were diluted using PBS.
The initial overnight incubation consisted of an applica-
tion of biotin and a 1:1,000 dilution of the rabbit anti-
mouse antibody MBS-2 (neutrophil-specific antibody
made in-house), with the latter omitted from control
slides. Following a PBS-T wash, the slides were incu-
bated with a 1:1,000 biotinylated goat anti-rabbit IgG so-
lution (Vector Laboratories Inc, Burlingame, CA, USA),
as a secondary antibody to label the bound MBS-2.
The avidin (A) biotinylated (B) horseradish peroxidase
macromolecular complex (C) was prepared and added in
a 1:100 dilution using the VectorElite ABC kit (Vector
Laboratories Inc, Burlingame, CA, USA) for 45 min.
After each stage, the slides were washed with PBS-T.
The substrate of the enzyme complex, diaminobenzidine
(DAB), was added with 125 μl of 30% hydrogen peroxide
and 250 ml of 0.1-M phosphate buffer to visualise the
peroxide labelling. The reaction localised to the ABC-
bound sites, producing a brown product. The sections
were then washed with PBS, overstaining was excluded by
microscopic examinations and Mayer’s haematoxylin
solution was added as a counterstain to aid neutrophil
identification.
RNA extraction
A single tissue sample was taken from the frozen
autoclaved Eppendorf tube containing a few pieces of
liver tissue dissected earlier on in the experiment. This
was transferred to another Eppendorf tube where
300 μl of RLT buffer containing 0.001% β-mercap-
toethanol (β-ME) was added. The β-ME is mixed with
the buffer to break up the disulphide bonds that sta-
bilise any ribonucleases present in the sample and as a
result irreversibly denatures any RNases present.
Using a motor-driven plastic pestle, the tissue samples
were then mixed with the buffer before a further
300 μl was added and transferred to QiaShredder® mini
spin columns (Qiagen, Venlo, Limburg, Netherlands).
These were centrifuged at maximum speed for 3 min to
homogenise the lysate as it passed through the column.
The lysate was then added to one volume of 70% ethanol
made up of RNAse free water to help precipitate out the
RNA. A 600 μl of the sample was taken and transferred to
an RNeasy® mini spin column sitting in a 2-ml collection
Losey et al. Journal of Neuroinflammation  (2015) 12:99 Page 9 of 10tube and centrifuged for 15 s at 10,000 rpm. This step was
repeated before washing with RW1 buffer and centrifu-
ging. The column was then treated with DNAse 1 for
15 min, using 10 μl of DNAse 1 diluted in 70 μl of buffer
per tissue sample, to remove any genomic DNA contam-
ination. The column was then washed again with RW1 be-
fore transferring the RNeasy column to a new un-capped
Eppendorf and applying RPE buffer. This step was re-
peated, and in each step, the columns were centrifuged,
working alongside the buffers in removing any remaining
contaminants. The RNeasy columns were dried by dis-
carding the supernatant and centrifuging the tubes at
maximum speed. Finally, the column was transferred to a
new collection tube where 50 μl of RNase free water was
added to the membrane before being centrifuged for
1 min at 10,000 rpm to elute the purified RNA. To pre-
serve it, they were transferred to a final Eppendorf and
stored at −80°C.cDNA production
The cDNA was synthesised using a Taqman Reverse Tran-
scription reagent kit (Applied Biosystems, Warrington,
UK) according to manufacturer’s instructions. In brief, the
concentration of the original RNA sample was determined
spectrophotometrically at 260 nm by diluting the purified
sample of RNA produced above 1:25 in RNase free water
and placing it in a spectrophotometer (Eppendorf,
Cambridge, UK). The samples were then diluted as appro-
priate to input 200 ng of RNA into the reverse transcrip-
tion reaction. The rest of the reverse transcription
mastermix was made up of multiscribe reverse transcript-
ase, random hexamers, magnesium chloride, reverse tran-
scriptase buffer, deoxynucleotides and an RNase inhibitor
to stop degradation. To control for any genomic DNA
contamination in subsequent PCR reactions, a control
tube was included in all batches of cDNA that contained
no reverse transcriptase. The tubes containing the master-
mix, and RNA samples were vortexed to mix them to-
gether and centrifuged to remove any bubbles that might
interfere with efficient transcription. They were then
placed in the progene machine where the temperature
sequence for processing them was 10 min at 25°C to re-
move any hexameric primers extended by reverse tran-
scriptase, 30 min at 48°C for reverse transcription and
5 min at 95°C to inactivate the reverse transcriptase
enzyme.
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